PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64

NCT04765436 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19 Vaccine

Interventions

BIOLOGICAL: PTX-COVID19-B
BIOLOGICAL: Placebo

Sponsor

Providence Therapeutics Holdings Inc.